Article and Video CATEGORIES

Cancer Journey

Search By

CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer
Author
GRACE Videos and Articles

Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some.

[powerpress]

CO-1686: Best Response in Phase 1 and early Phase 2 expansion cohort patients

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora